<SEC-DOCUMENT>0001193125-20-046839.txt : 20200225
<SEC-HEADER>0001193125-20-046839.hdr.sgml : 20200225
<ACCEPTANCE-DATETIME>20200224191732
ACCESSION NUMBER:		0001193125-20-046839
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20200224
FILED AS OF DATE:		20200225
DATE AS OF CHANGE:		20200224

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DBV Technologies S.A.
		CENTRAL INDEX KEY:			0001613780
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36697
		FILM NUMBER:		20646634

	BUSINESS ADDRESS:	
		STREET 1:		177-181 AVENUE PIERRE BROSSOLETTE
		CITY:			MONTROUGE
		STATE:			I0
		ZIP:			92120
		BUSINESS PHONE:		33(0)155427878

	MAIL ADDRESS:	
		STREET 1:		177-181 AVENUE PIERRE BROSSOLETTE
		CITY:			MONTROUGE
		STATE:			I0
		ZIP:			92120
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d845903d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Month of February 2020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-36697</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>DBV TECHNOLOGIES S.A. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">177-181</FONT> avenue Pierre Brossolette </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>92120 Montrouge France </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">40-F:</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#9746;&nbsp;Form
<FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744;&nbsp;Form</FONT> <FONT STYLE="white-space:nowrap">40-F</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated February&nbsp;24, 2020.</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5"><B>DBV TECHNOLOGIES S.A</B>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: February&nbsp;24, 2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ramzi Benamar</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ramzi Benamar</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1&nbsp;&nbsp;&nbsp;&nbsp; </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g845903page1a.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g845903page1b.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g845903page1c.jpg" ALT="LOGO">
</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Montrouge, France, February
24, 2020</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DBV Technologies to Present Detailed Safety and Efficacy Data of Viaskin Peanut at AAAAI 2020 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DBV Technologies (Euronext: DBV &#150; ISIN: FR0010417345 &#150; Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that
abstracts highlighting clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data from its Viaskin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform will be presented at the American Academy of Allergy,
Asthma&nbsp;&amp; Immunology (AAAAI) 2020 Annual Meeting in Philadelphia, PA, March 13 &#150; 16. Six abstracts have been accepted, including three oral presentations and three poster presentations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>&#147;We&#146;re excited to be returning to AAAAI to share topline data on Viaskin Peanut from the largest long-term study in the field of peanut allergy
immunotherapy to date,&#148; </I>said<I> </I><B>Dr.</B><I></I><B></B><I></I><B>&nbsp;Pharis Mohideen</B><I>, </I>Chief Medical Officer of DBV Technologies<I>. &#147;We also will present data on safety, quality of life and reducing the risk of
reactions to accidental exposures. These data reflect our ongoing commitment to understanding the science and treatment of peanut allergy to improve the lives of patients in a simple and convenient way.&#148; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Viaskin Peanut is the Company&#146;s lead product candidate designed to potentially reduce the risk of life-threatening allergic reactions due to accidental
exposure to peanuts. An investigational <FONT STYLE="white-space:nowrap">non-invasive,</FONT> once-daily, epicutaneous patch, Viaskin Peanut seeks to deliver microgram quantities of peanut antigen to activate the immune system. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Abstracts of Interest: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Epicutaneous Immunotherapy for
Peanut Allergy Clinical Data and Analyses </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;Open-Label <FONT STYLE="white-space:nowrap">Follow-Up</FONT> of the PEPITES Study (PEOPLE) to
Evaluate the Long-Term Efficacy and Safety of Epicutaneous Peanut Immunotherapy in Peanut-Allergic Children&#148;</B>&nbsp;will be presented by David Fleischer, MD, Director, Allergy and Immunology Center and Section Head, Children&#146;s Hospital
Colorado. (Poster Presentation) </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g845903g0225004535553.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Abstract Number: 449 </I></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Session Title: Treatment of Food Allergy </I></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Location: Convention Center, 200 Level, Hall D </I></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Presentation Date: Sunday, March&nbsp;15, 2020 </I></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Presentation Time: <FONT STYLE="white-space:nowrap">9:45-10:45</FONT> AM ET </I></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;Results of the REALISE (Real-life Use and Safety of EPIT) Study: A Multicenter Blinded Randomized Controlled Trial Investigating the Safety of
Epicutaneous Immunotherapy for Peanut Allergy in Peanut-Allergic Children&#148;</B>&nbsp;will be presented by Jacqueline Pongracic, MD, Head, Allergy and Immunology, Ann&nbsp;&amp; Robert H. Lurie Children&#146;s Hospital of Chicago, Professor of
Pediatrics and Medicine, Northwestern University Feinberg School of Medicine. (Oral Presentation) </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Abstract Number: 257 </I></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Session Number: 2605 </I></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Session Title: Advances in the Treatment of Peanut Allergy </I></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Location: Convention Center, 400 Level, Terrace Ballroom I </I></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Presentation Date: Saturday, March&nbsp;14, 2020 </I></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Presentation Time: <FONT STYLE="white-space:nowrap">2:15-2:30</FONT> PM ET </I></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;Modeled Quantitative Risk Reduction Through Epicutaneous Immunotherapy for Peanut Allergy: Restaurant Meal Preparation with Shared Cooking Utensils
and Equipment&#148;</B><B></B>&nbsp;will be presented by Benjamin C. Remington, PhD, University of Nebraska-Lincoln Food Allergy Research and Resource Program, and the Remington Consulting Group B.V., The Netherlands. (Poster Presentation) </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Abstract Number: 451 </I></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Session Title: Treatment of Food Allergy </I></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Location: Convention Center, 200 Level, Hall D </I></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Presentation Date: Sunday, March&nbsp;15, 2020 </I></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Presentation Time: <FONT STYLE="white-space:nowrap">9:45-10:45</FONT> AM ET </I></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;Food Allergy Quality of Life Questionnaires for Assessment of Health-Related Quality of Life in Clinical Food Allergy Treatment Studies: Use of Item
Response Theory&#148;</B>&nbsp;will be presented by Audrey Dunn-Galvin, PhD, School of Applied Psychology, University College Cork, College Road, Cork City, Ireland. (Poster Presentation) </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Abstract Number: 444</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Session Title: Treatment of Food Allergy </I></P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g845903g0225004535553.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Location: Convention Center, 200 Level, Hall D</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Presentation Date: Sunday, March</I><I></I><I>&nbsp;15, 2020</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Presentation Time: <FONT STYLE="white-space:nowrap">9:45-10:45</FONT> AM ET</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Epicutaneous Immunotherapy (EPIT) Scientific Research </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>&#147;</I><B>Role</B><B></B><B>&nbsp;of</B><B></B><B>&nbsp;Langerhans
Cells</B><B></B><B>&nbsp;in</B><B></B><B>&nbsp;the</B><B></B><B>&nbsp;Formation</B><B></B><B>&nbsp;of</B><B></B><B>&nbsp;Germinal Center and Modulation of Humoral Immunity</B><B></B><B>&nbsp;During</B><B></B><B>&nbsp;Epicutaneous
Immunotherapy&#148;</B>&nbsp;will be presented by Vincent Dioszeghy, PhD, DBV Technologies. (Oral Presentation) </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Abstract Number: 266</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Session Number: 2607</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Session Title: Mechanisms and Treatment Effect of Immunotherapy</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Location: Convention Center, 100 Level, Room 115</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Presentation Date: Saturday, March</I><I></I><I>&nbsp;14, 2020</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Presentation Time: <FONT STYLE="white-space:nowrap">2:00-2:15</FONT> PM ET</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>&#147;</I><B>Mechanisms</B><B></B><B>&nbsp;of</B><B></B><B>&nbsp;Allergen</B><B></B><B>&nbsp;Capture by</B><B></B><B>&nbsp;Skin
DC</B><B></B><B>&nbsp;Differ between na&iuml;ve and sensitized individuals in a <FONT STYLE="white-space:nowrap">specific-IgG</FONT> dependent manner&#148;</B>&nbsp;will be presented by Pierre-Louis Herv&eacute;, PhD, DBV Technologies. (Oral
Presentation) </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Abstract Number: 527</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Session Number: 3603</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Session Title: Immunology of Allergy </I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Location: Convention Center, 100 Level, Room 113</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Presentation Date: Sunday, March</I><I></I><I>&nbsp;15, 2020</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Presentation Time: <FONT STYLE="white-space:nowrap">2:30-2:45</FONT> PM ET</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About DBV Technologies</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DBV Technologies is developing
Viaskin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT<SUP
STYLE="font-size:85%; vertical-align:top">&#153;</SUP>, DBV&#146;s method of delivering biologically active compounds to the immune system through intact skin. With this new class of <FONT STYLE="white-space:nowrap">non-invasive</FONT> product
candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV&#146;s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is
also pursuing a human <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> clinical trial of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform
in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company&#146;s ordinary shares are traded on
segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company&#146;s ADSs (each representing <FONT STYLE="white-space:nowrap">one-half</FONT> of one ordinary share) are traded on the Nasdaq Global
Select Market (Ticker: DBVT). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g845903g0225004535553.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements, including statements about the potential of the EPIT platform and Viaskin<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Peanut as a treatment for peanut-allergic children. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Factors that could cause
actual results to differ materially from those described or projected herein include risk associated with uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals. A further list
and description of these risks, uncertainties and other risks can be found in the Company&#146;s regulatory filings with the French Autorit&eacute; des March&eacute;s Financiers and U.S. Securities and Exchange Commission, including in the
Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2018. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which
speak only as of the date hereof. The Company undertakes no obligation to update or revise forward-looking statements as a result of new information, future events or circumstances, or otherwise, except as required by law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DBV Investor Relations Contact </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sara Blum Sherman </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Director, Investor Relations&nbsp;&amp; Strategy </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1&nbsp;212-271-0740</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">sara.sherman@dbv-technologies.com</FONT></U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DBV Media Contact </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Joe Becker </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VP, Global Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1&nbsp;646-650-3912</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">joseph.becker@dbv-technologies.com</FONT></U> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g845903g0225004535553.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g845903g0225004535553.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "S QH# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH .?0_E1SZ'\J^
ML_\ A!]#_P"?=_\ ONC_ (0?0_\ GW?_ +[KSOK=?_GVO_ O_M3O^K8?_GX_
M_ ?_ +8^3.?0_E1SZ'\J^L_^$'T/_GW?_ONC_A!]#_Y]W_[[H^MU_P#GVO\
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M_ ?_ +8^3.?0_E1SZ'\J^L_^$'T/_GW?_ONC_A!]#_Y]W_[[H^MU_P#GVO\
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M_ ?_ +8^3.?0_E1SZ'\J^L_^$'T/_GW?_ONC_A!]#_Y]W_[[H^MU_P#GVO\
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M_ ?_ +8^3.?0_E1SZ'\J^L_^$'T/_GW?_ONC_A!]#_Y]W_[[H^MU_P#GVO\
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M_ ?_ +8^3.?0_E1SZ'\J^L_^$'T/_GW?_ONC_A!]#_Y]W_[[H^MU_P#GVO\
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M_ ?_ +8^3.?0_E1SZ'\J^L_^$'T/_GW?_ONC_A!]#_Y]W_[[H^MU_P#GVO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*UDD25 \;!E89!!R#4RWN7'L.K-UXC^QYEQN+%0!Z\@_TK19E12SL%4<DDX
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)+=3RQ7'V@23S%F+[2GTQACP !3O$5F9DGB:^A<6;:;%)J ODLRB3D1_-$9
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5%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g845903page1a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g845903page1a.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@04 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0,* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@#ZJ_P"%>:/_ ,];K_OM?_B:^;_LVEW?]?(^C_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
M (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W
M?\$/^%>:/_SUNO\ OM?_ (FC^S:7=_U\@_M>OV7W?\$/^%>:/_SUNO\ OM?_
4 (FC^S:7=_U\@_M>OV7W?\$__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g845903page1b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g845903page1b.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MPFTMREI?B_P]K5Q]GT[6+6XG[1J^&/T!Y--PDMT"DGL<S\,_^0AXR_[#<_\
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7RL0N=JY8D@#)P.G)]:3;8)6+U(9__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g845903page1c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g845903page1c.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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@0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
